Efimosfermin alfa in adults with liver impairment from fatty liver disease
Tests how the body handles efimosfermin alfa in adults with fatty liver disease.
Plain-language title generated from the registry record
Registry title: A Study of Efimosfermin Alfa in Adults With Hepatic Impairment
Key facts
- Where
- Houston, Miami Lakes, Rialto, San Antonio, and Tampa, United StatesSee the 5 sites
- Phase
- Phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT07358546, who can take part
Where in United States
- HoustonHouston, United StatesTaking people
- Miami LakesMiami Lakes, United StatesTaking people
- RialtoRialto, United StatesTaking people
- San AntonioSan Antonio, United StatesTaking people
- TampaTampa, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- GlaxoSmithKline
- Trial code
- NCT07358546
- Record updated
- 5 November 2026
- Original description
This study is designed to study the pharmacokinetic (PK) and safety profiles of a single dose of efimosfermin alfa in participants with varying degrees of Hepatic Impairment (HI) (assessed by Child-Pugh score) due to steatotic liver disease, with and without significant alcohol consumption.Read full original descriptionShow less
A Phase 1, Open-label, Single-dose Study to Evaluate the Pharmacokinetics and Safety of Efimosfermin Alfa in Adults With Varying Degrees of Hepatic Impairment Due to Steatotic Liver Disease
This study is designed to study the pharmacokinetic (PK) and safety profiles of a single dose of efimosfermin alfa in participants with varying degrees of Hepatic Impairment (HI) (assessed by Child-Pugh score) due to steatotic liver disease, with and without significant alcohol consumption.
Inclusion: Between 18 years and 70 years of age inclusive; Body Mass Index (BMI) within the range 23-40 kilogram per square meter (kg/m\^2); Male or female participants; Participant has liver cirrhosis with a grade of hepatic impairment that can be classified as a discrete Child-Pugh class. Participants must:; Have a clinical diagnosis of liver cirrhosis in the participant's medical history corroborated by previous liver biopsy, medical imaging or compatible biochemical profile, and; Be classed during Screening as one of the following Child-Pugh classes:; Child-Pugh B: Score 7-9 or; Child-Pugh C: Score 10-15; Chronic (greater than [>] 6 months) HI which is currently stable (no acute episodes of illness within the previous 1 month prior to Screening (Visit 1) due to deterioration in hepatic function). Participants must also remain stable throughout the Screening period. Assessment of the stability of the participant's hepatic function will be determined by the investigator.
Exclusion: History of gastric or esophageal variceal bleeding within the past 6 months and for which varices have not been adequately treated with medication and/or surgical procedures; History or presence of drug abuse; Use of other investigational drugs at the time of screening, or within 5 half-lives or 30 days prior to study intervention, whichever was longer; or longer if required by local regulations; Have previously taken efimosfermin alfa; History of extrahepatic disorders possibly related to etiology of cirrhosis; History of cryoglobulinemia; Participants with refractory encephalopathy or significant central nervous system disease; Other primary causes of liver disease. Steatotic liver disease must be the primary cause of liver disease; Current, or history of known hepatocellular carcinoma (HCC); Presence of hepatopulmonary or hepatorenal syndrome; Presence of primarily cholestatic liver diseases; History of pancreatic injury, pancreatitis, or other pancreatic disease; History of liver transplantation, or active on the liver transplant waiting list; Participants with signs of active infection; History of adrenal gland disease or using treatment that affects the hypothalamic-pituitary-adrenal axis; History of significant bone disease such as osteoporosis; Participants with Alanine Aminotransferase (ALT) value >3 times (x) upper limit of normal (ULN); Participants with Aspartate aminotransferase (AST) value >=300 Units/Liter; Participants with estimated glomerular filtration rate (eGFR) (Chronic Kidney Disease Epidemiology [CKD-Epi] 2021) <45 milliliter/minute/1.73 square meter (mL/min/1.73m\^2); Average of triplicate QT interval corrected for heart rate using Fridericia formula (QTcF) >480 milliseconds (msec) (for male and female participants) at Screening; Participants with Grade 3 ascites or refractory ascites; Clinically significant abnormalities affecting physical health in medical history, or on physical examination, that could interfere with or for which treatment could interfere with the conduct of the study, or that would, in the opinion of the investigator, pose an unacceptable risk to the participant in this study; Participants with transjugular intrahepatic portosystemic shunt (TIPS) placement; Evidence of symptomatic or complicated cholecystitis; Psychosocial features that, in the opinion of the investigator, increase the likelihood of loss to follow-up; For participants in the MASH with alcohol category, significant risk of withdrawal symptoms.